ITI-214 Market Size, Forecast, and Emerging Insight - 2032

This “ITI-214 Market Size, Forecast, and Emerging Insight − 2032” report provides comprehensive insights about ITI-214 for Parkinson's disease in the seven major markets. A detailed picture of the ITI-214 for Parkinson's Disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the ITI-214 for Parkinson's Disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ITI-214 market forecast analysis for Parkinson's disease in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Parkinson's disease.

Drug Summary

Lenrispodun/ ITI-214 is a potent and selective phosphodiesterase type 1 (PDE1) Inhibitor and is the lead compound in the company's PDE1 portfolio. ITI-214 works by blocking the breakdown of cyclic nucleotides (cAMP, cGMP), thus allowing these molecules to build up in the cells and to exert important functions.

ITI-214 has been generally well tolerated with a favorable safety profile in clinical trials. Currently, ITI-214 is being investigated in a Phase II trial in patients with motor fluctuations due to Parkinson's disease and is also being developed for the treatment of heart failure.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the ITI-214 description, mechanism of action, dosage and administration, research and development activities in Parkinson's disease.
• Elaborated details on ITI-214 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ITI-214 research and development activities in Parkinson's disease across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around ITI-214.
• The report contains forecasted sales of ITI-214 for Parkinson's disease till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Parkinson's disease.
• The report also features the SWOT analysis with analyst views for ITI-214 in Parkinson's disease.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis a team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ITI-214 Analytical Perspective

In-depth ITI-214 Market Assessment

This report provides a detailed market assessment of ITI-214 for Parkinson's disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

ITI-214 Clinical Assessment

The report provides the clinical trials information of ITI-214 for Parkinson's disease covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Parkinson's disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ITI-214 dominance.
• Other emerging products for Parkinson's disease are expected to give tough market competition to ITI-214 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ITI-214 in Parkinson's disease.
• This in-depth analysis of the forecasted sales data of ITI-214 from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ITI-214 in Parkinson's disease.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of ITI-214?
• What is the clinical trial status of the study related to ITI-214 in Parkinson's disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ITI-214 development?
• What are the key designations that have been granted to ITI-214 for Parkinson's disease?
• What is the forecasted market scenario of ITI-214 for Parkinson's disease?
• What are the forecasted sales of ITI-214 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to ITI-214 for Parkinson's disease?
• Which are the late-stage emerging therapies under development for the treatment of Parkinson's disease?

This product will be delivered within 2 business days.